105 related articles for article (PubMed ID: 20505280)
1. Coexistence of mucosa-associated lymphoid tissue lymphoma with plasma cell features and adenocarcinoma cells in pleural fluid.
Ohno H
J Clin Exp Hematop; 2010; 50(1):75-7. PubMed ID: 20505280
[No Abstract] [Full Text] [Related]
2. t(11;18)(q21;q21)-positive advanced-stage MALT lymphoma associated with monoclonal gammopathy: resistance to rituximab or rituximab-containing chemotherapy.
Ohno H; Isoda K
J Clin Exp Hematop; 2008 Nov; 48(2):47-54. PubMed ID: 19039196
[TBL] [Abstract][Full Text] [Related]
3. Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab.
Salar A; Bellosillo B; Serrano S; Besses C
J Clin Oncol; 2005 Oct; 23(29):7361-2; author reply 7362-3. PubMed ID: 16210674
[No Abstract] [Full Text] [Related]
4. Successful rituximab monotherapy for API2-MALT1 fusion positive primary mucosa-associated lymphoid tissue lymphoma of the transverse colon in a patient with liver cirrhosis.
Yamada M; Kawahara H; Shiroeda H; Tsuchishima M; Masaki Y; Sato K; Takase S
Scand J Gastroenterol; 2008; 43(6):761-4. PubMed ID: 18569996
[No Abstract] [Full Text] [Related]
5. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
6. Transformation of MALT lymphoma to pure plasma cell histology: possible association with anti-CD20 antibody treatment.
Klein N; Elis A; Radnay J; Zemer R; Klein A; Lishner M
Isr Med Assoc J; 2009 Nov; 11(11):703-4. PubMed ID: 20108563
[No Abstract] [Full Text] [Related]
7. Treatment of localized oral MALT lymphoma by rituximab: a case report.
Yamagata K; Onizawa K; Kojima H; Yoshida H
Oral Maxillofac Surg; 2008 Dec; 12(4):227-30. PubMed ID: 18830723
[TBL] [Abstract][Full Text] [Related]
8. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome.
Harner KC; Jackson LW; Drabick JJ
Rheumatology (Oxford); 2004 Oct; 43(10):1309-10. PubMed ID: 15448217
[No Abstract] [Full Text] [Related]
9. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland.
Heinz C; Merz H; Nieschalk M; Mueller-Miny H; Koch P; Heiligenhaus A
Br J Ophthalmol; 2007 Nov; 91(11):1563-4. PubMed ID: 17947275
[No Abstract] [Full Text] [Related]
10. Contemplating the Diagnostic Certainty of Primary Iris Mucosa-Associated Lymphoid Tissue Lymphoma.
Margo CE
JAMA Ophthalmol; 2015 Aug; 133(8):969-70. PubMed ID: 25950116
[No Abstract] [Full Text] [Related]
11. Contemplating the Diagnostic Certainty of Primary Iris Mucosa-Associated Lymphoid Tissue Lymphoma—Reply.
Demirci H; Elner VM
JAMA Ophthalmol; 2015 Aug; 133(8):970. PubMed ID: 25950277
[No Abstract] [Full Text] [Related]
12. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis.
Niscola P; Palumbo R; Scaramucci L; Tendas A; Cupelli L; Giovannini M; Piccioni D; Dentamaro T; Perrotti AP; de Fabritiis P
Cancer Chemother Pharmacol; 2009 Mar; 63(4):759-60. PubMed ID: 18500519
[No Abstract] [Full Text] [Related]
13. Possible clinical effects of macrolides on the treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma.
Yatera K; Ishimatsu Y; Sakamoto N; Mukae H
Int J Hematol; 2016 Feb; 103(2):251-2. PubMed ID: 26590918
[No Abstract] [Full Text] [Related]
14. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.
Seker M; Bilici A; Ustaalioglu BO; Salman T; Sonmez B; Canpolat NA; Salepci T; Gumus M; Yaylaci M
Leuk Res; 2009 Sep; 33(9):e154-6. PubMed ID: 19386361
[No Abstract] [Full Text] [Related]
15. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
Seker M; Ustaalioğlu BB; Bilici A; Yildirim ME; Kefeli U; Barisik NO; Tamer I; Gumus M
Leuk Res; 2010 Jul; 34(7):e160-3. PubMed ID: 20219245
[No Abstract] [Full Text] [Related]
16. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
Nückel H; Meller D; Steuhl KP; Dührsen U
Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
[TBL] [Abstract][Full Text] [Related]
17. A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
Kiesewetter B; Neuper O; Mayerhoefer ME; Dolak W; Lukas J; Simonitsch-Klupp I; Raderer M
Hematol Oncol; 2018 Feb; 36(1):49-55. PubMed ID: 28695630
[TBL] [Abstract][Full Text] [Related]
18. Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two?
Neubauer A; Huynh M
Leuk Lymphoma; 2011 Dec; 52(12):2203-4. PubMed ID: 21824053
[No Abstract] [Full Text] [Related]
19. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial.
Jäger G; Neumeister P; Quehenberger F; Wöhrer S; Linkesch W; Raderer M
Ann Oncol; 2006 Nov; 17(11):1722-3. PubMed ID: 16766585
[No Abstract] [Full Text] [Related]
20. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
